Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel, Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Efficacy and Safety of MT10109L Versus BOTOX® in Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

NCT03894748 is registered in ClinicalTrials.gov with Medy-Tox as lead sponsor.

NCT NCT03894748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03894748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel, Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Efficacy and Safety of MT10109L Versus BOTOX® in Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)
Lead sponsor
Medy-Tox
Phase
Phase 2/3
Overall status
Completed
Start date
December 31, 2011
Completion date
October 31, 2012
Enrollment
168 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glabella line severity